IL2RA and lymphoma: Although daclizumab has FDA approval for use in organ transplantation, it has also been demonstrated that applying daclizumab in clinical trials are providing an effective therapeutic approach for patients with CD25 expressing leukemia and lymphoma (3, 12, 89, 90).